Griffith Institute for Drug Discovery

GRIDD tackles devastating diseases using the unique Compounds Australia and Nature Bank resources, and an extensive global network of partners.

We innovate at the chemistry-biology interface, and collaborate with academia, the community, government, health, not-for-profits and industry. We thank our supporters including the Clem Jones Foundation, Perry Cross Spinal Research Foundation, Aegium, Parkinson’s Queensland, and the Queensland and Australian Governments.

We are proud to foster the next generation of drug discovery scientists.

Please partner with us in our search for revolutionary new treatments.

GRIDD brochure

Unique resources

The Griffith Institute for Drug Discovery has unique resources available for use.

NatureBank

NatureBank, a resource based on natural products, is ready for High Throughput Screening against any disease.

Find out more

Compounds Australia

Representing the nation’s compound collection, it connects chemists with biologists for drug discovery.

Find out more

Unique technology

Our key technologies include High Throughput Screening, Fourier Transform Mass Spectrometry and Fragment-Based Screening.

Find out more

NatureBank flyer

Research Highlights

Welcome to GRIDD

Find out more from Director Professor Jennifer L. Martin.

Australian of the Year 2017 Professor Emeritus Alan Mackay-Sim

Alan Mackay-Sim is a world-renowned trailblazer in cell transplantation, who paved the way for innovative research to repair damaged spinal cords to return the gift of movement to paralysed people.

Antibiotic Resistance

Director Professor Jenny Martin, who was elected to the Australian Academy of Science in May 2017, talks about her research into the rapidly growing problem of antibiotic resistance.

Compounds Australia flyer

Our research

The Institute strives for excellence through supporting our research teams to work collaboratively to advance the discovery of new drugs. Innovation is encouraged through cross-disciplinary rigour and global collaboration. Read more about our work combating specific diseases and disabilities, below.

Find out more about our research

Directions in Drug Discovery

Cancer

An estimated 130,470 new cases of cancer were diagnosed in Australia in 2016, with that number set to rise to 150,000 by 2020. Professors Vicky Avery, Sally-Ann Poulsen and Associate Professor Rohan Davis are working to discover compounds that are active against breast, prostate and pancreatic cancer.

Infectious diseases

Infectious diseases kill more than one million people annually. GRIDD’s Professors Kathy Andrews, Vicky Avery and Ronald Quinn are seeking new drugs to treat diseases like malaria and TB, while Director Professor Jenny Martin is exploring new approaches to treat complicated urinary tract infections as well as melioidosis, a common disease in northern Australia.

Parkinson's disease

About 70,000 Australians are affected by this progressive disease of the nervous system. Professor George Mellick’s research explores the genetics of Parkinsonism and the interactions between genetic and environmental factors that contribute to onset and development of the disease.

Drug resistance

Professor Sally-Ann Poulsen has discovered a new way to reverse multidrug resistance in cancer. While Director Professor Jenny Martin is exploring how to disarm bacteria so they cannot cause disease.

Spinal Cord Injury Repair

Up to half a million people globally suffer from spinal cord injury. GRIDD’s Associate Professor James St John in the Clem Jones Centre for Neurobiology and Stem Cell Research offers hope of new therapies. This research was pioneered by 2017 Australian of the Year, Professor Emeritus Alan Mackay-Sim.

Our researchers

Stay up to date

Example inputs

Join us

We are supported by a growing number of sponsors who share our vision for the future